These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

978 related articles for article (PubMed ID: 22119592)

  • 21. The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.
    Melegaro A; Marziano V; Del Fava E; Poletti P; Tirani M; Rizzo C; Merler S
    BMC Med; 2018 Jul; 16(1):117. PubMed ID: 30012132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.
    Sauboin C; Holl K; Bonanni P; Gershon AA; Benninghoff B; Carryn S; Burgess MA; Wutzler P
    BMC Infect Dis; 2019 Feb; 19(1):126. PubMed ID: 30727971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008.
    Chao DY; Chien YZ; Yeh YP; Hsu PS; Lian IB
    Epidemiol Infect; 2012 Jun; 140(6):1131-40. PubMed ID: 21906410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.
    Wolfson LJ; Daniels VJ; Pillsbury M; Kurugöl Z; Yardimci C; Kyle J; Dinleyici EC
    PLoS One; 2019; 14(8):e0220921. PubMed ID: 31408505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Varicella vaccination in England and Wales: cost-utility analysis.
    Brisson M; Edmunds WJ
    Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom.
    Brisson M; Edmunds WJ; Law B; Gay NJ; Walld R; Brownell M; Roos LL; De Serres G
    Epidemiol Infect; 2001 Oct; 127(2):305-14. PubMed ID: 11693508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program.
    Tanuseputro P; Zagorski B; Chan KJ; Kwong JC
    Vaccine; 2011 Nov; 29(47):8580-4. PubMed ID: 21939721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of varicella vaccination programs: an update of the literature.
    Rozenbaum MH; van Hoek AJ; Vegter S; Postma MJ
    Expert Rev Vaccines; 2008 Aug; 7(6):753-82. PubMed ID: 18665775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunization of adults against varicella and herpes zoster].
    Hanslik T; Blanchon T; Alvarez FP
    Rev Med Interne; 2007 Mar; 28(3):166-72. PubMed ID: 17270316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of vaccination on the epidemiology of varicella zoster virus.
    Edmunds WJ; Brisson M
    J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased varicella and increased herpes zoster incidence at a sentinel medical deputising service in a setting of increasing varicella vaccine coverage in Victoria, Australia, 1998 to 2012.
    Kelly HA; Grant KA; Gidding H; Carville KS
    Euro Surveill; 2014 Oct; 19(41):. PubMed ID: 25345520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model.
    Rafferty ERS; McDonald W; Osgood ND; Doroshenko A; Farag M
    Value Health; 2021 Jan; 24(1):50-60. PubMed ID: 33431153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia.
    Gao Z; Gidding HF; Wood JG; MacIntyre CR
    Epidemiol Infect; 2010 Apr; 138(4):457-68. PubMed ID: 19781116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013.
    Hobbelen PH; Stowe J; Amirthalingam G; Miller L; van Hoek AJ
    J Infect; 2016 Sep; 73(3):241-53. PubMed ID: 27283754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.
    Poletti P; Melegaro A; Ajelli M; Del Fava E; Guzzetta G; Faustini L; Scalia Tomba G; Lopalco P; Rizzo C; Merler S; Manfredi P
    PLoS One; 2013; 8(4):e60732. PubMed ID: 23613740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Universal varicella vaccination increased the incidence of herpes zoster in the child-rearing generation as its short-term effect.
    Toyama N; Shiraki K;
    J Dermatol Sci; 2018 Oct; 92(1):89-96. PubMed ID: 30041832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV.
    Brisson M; Edmunds WJ; Gay NJ
    J Med Virol; 2003; 70 Suppl 1():S31-7. PubMed ID: 12627484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Herpes zoster in the context of varicella vaccination - An equation with several variables.
    Wutzler P; Casabona G; Cnops J; Akpo EIH; Safadi MAP
    Vaccine; 2018 Nov; 36(46):7072-7082. PubMed ID: 30309745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.